Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 vehicle on file, newest listing first
Jakob Dupont, M.D. (2) 57 Director Meenu Karson 50 Director Gordon Ringold, Ph.D. (1)(3) 71 Director Scott Smith (2)(3) 60 Director Samuel Wertheimer, Ph.D. (4) 63 Director Dan Zabrowski, Ph.D. (1)(2) 63 Director (1) Member of the audit committee. (2) Member of the compensation committee. (3) Member of the corporate governance and nominating committee. (4) Chair of the Company Board. (4) Director of Brookline Capital Acquisition Corp. from January 2021 to July 2022. Executive Officers Xiaodong Yang, M.D., Ph.D., Chief Executive Officer and Director. Dr. Yang has served as the Company’s Chief Executive Officer and as a member of the Board since July 2022. He also served as the Company’s President from July 2022 to February 2023. Dr. Yang has served as Legacy Apexigen’s President and Chief Executive Officer since July 2010 and as a member of Legacy Apexigen’s board of directors since July 2010.
This record is keyed to SEC CIK 0001553335 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 24 institutional-holder rows on these vehicles, under 17 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.